{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:53:47Z","timestamp":1761173627824,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.purol.2018.03.001","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T19:17:49Z","timestamp":1523906269000},"page":"361-369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effets cardio-vasculaires des traitements anticholinergiques \u00e0 vis\u00e9e v\u00e9sicale chez la personne \u00e2g\u00e9e\u00a0: une revue"],"prefix":"10.1016","volume":"28","author":[{"given":"C.","family":"Chesnel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Charlanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hentzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Turmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Biardeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Brochard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Campagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Capon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Deffieux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Fatton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Gam\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Jeandel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Kerdraon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Manceau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mezzadri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mongiat-Artus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-C.","family":"Petit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Peyronnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-M.","family":"Soler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Thuillier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-M.","family":"Vetel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Robain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Amarenco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.purol.2018.03.001_bib0230","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.purol.2018.03.001_bib0235","doi-asserted-by":"crossref","first-page":"b4904","DOI":"10.1136\/bmj.b4904","article-title":"Health and disease in 85\u00a0year olds: baseline findings from the Newcastle 85+ cohort study","volume":"339","author":"Collerton","year":"2009","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.purol.2018.03.001_bib0240","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.purol.2013.11.016","article-title":"[Guidelines concerning urinary incontinence in elderly: construction and validation of GRAPPPA algorithm]","volume":"24","author":"Amarenco","year":"2014","journal-title":"Progres En Urol J"},{"issue":"9","key":"10.1016\/j.purol.2018.03.001_bib0245","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.purol.2018.03.001_bib0250","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/nau.22602","article-title":"Urinary incontinence in frail elderly persons: Report from the 5th International Consultation on Incontinence","volume":"34","author":"Wagg","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.purol.2018.03.001_bib0255","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.archger.2016.11.006","article-title":"Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: a systematic review and meta-analysis","volume":"69","author":"Vouri","year":"2017","journal-title":"Arch Gerontol Geriatr"},{"issue":"11","key":"10.1016\/j.purol.2018.03.001_bib0260","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.purol.2014.06.003","article-title":"[Impact on cognitive function of anticholinergic drugs used for the treatment of overactive bladder in the elderly]","volume":"24","author":"Kerdraon","year":"2014","journal-title":"Progres En Urol"},{"issue":"6","key":"10.1016\/j.purol.2018.03.001_bib0265","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","article-title":"Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults","volume":"73","author":"Risacher","year":"2016","journal-title":"JAMA Neurol"},{"issue":"Suppl 2","key":"10.1016\/j.purol.2018.03.001_bib0270","first-page":"S80","article-title":"Muscarinic receptors in the bladder: from basic research to therapeutics","volume":"147","author":"Hegde","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.purol.2018.03.001_bib0275","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2125.2010.03813.x","article-title":"Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction","volume":"72","author":"Andersson","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.purol.2018.03.001_bib0280","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1517\/14740338.2013.813016","article-title":"Cardiovascular effects of antimuscarinic agents in overactive bladder","volume":"12","author":"Rosa","year":"2013","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.purol.2018.03.001_bib0285","first-page":"223","article-title":"The muscarinic receptor subtypes in human blood vessels","volume":"56","author":"Walch","year":"2001","journal-title":"Therapie"},{"issue":"8","key":"10.1016\/j.purol.2018.03.001_bib0290","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00192-011-1411-6","article-title":"Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity","volume":"22","author":"Glavind","year":"2011","journal-title":"Int Urogynecology J"},{"issue":"4","key":"10.1016\/j.purol.2018.03.001_bib0295","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/1074248408325404","article-title":"Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants>or=50\u00a0years","volume":"13","author":"Olshansky","year":"2008","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"04","key":"10.1016\/j.purol.2018.03.001_bib0300","doi-asserted-by":"crossref","DOI":"10.3834\/uij.1944-5784.2009.08.07","article-title":"Validation of the Differential Cardiovascular Effects of the Antimuscarinic Agents Darifenacin and Tolterodine in a Randomized, Placebo-Controlled, 3-Way Crossover Study","volume":"02","author":"Olshansky","year":"2009","journal-title":"UroToday Int J"},{"issue":"5","key":"10.1016\/j.purol.2018.03.001_bib0305","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00345-010-0513-y","article-title":"The effect of tolterodine 4\u00a0and 8mg on the heart rate variability in healthy subjects","volume":"28","author":"Schiffers","year":"2010","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.purol.2018.03.001_bib0310","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1476-5381.2011.01367.x","article-title":"Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk","volume":"164","author":"Varr\u00f3","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.purol.2018.03.001_bib0315","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.amjcard.2008.08.071","article-title":"Relation of heart rate at rest and long-term (>20years) death rate in initially healthy middle-aged men","volume":"103","author":"Jouven","year":"2009","journal-title":"Am J Cardiol"},{"issue":"11\u00a0Pt 1","key":"10.1016\/j.purol.2018.03.001_bib0320","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0895-7061(04)00897-0","article-title":"Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study","volume":"17","author":"Hozawa","year":"2004","journal-title":"Am J Hypertens"},{"issue":"2","key":"10.1016\/j.purol.2018.03.001_bib0325","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-410X.2009.09073.x","article-title":"Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder","volume":"106","author":"Andersson","year":"2010","journal-title":"BJU Int"},{"issue":"260","key":"10.1016\/j.purol.2018.03.001_bib0330","first-page":"1","article-title":"Summary health statistics for U.S. adults: national health interview survey, 2012","author":"Blackwell","year":"2014","journal-title":"Vital Health Stat 10"},{"issue":"8","key":"10.1016\/j.purol.2018.03.001_bib0335","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1532-5415.2011.03491.x","article-title":"Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study","volume":"59","author":"Fox","year":"2011","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"10.1016\/j.purol.2018.03.001_bib0340","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40266-016-0399-5","article-title":"Antimuscarinic medication use in elderly patients with overactive bladder","volume":"33","author":"Kachru","year":"2016","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.purol.2018.03.001_bib0345","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.archger.2014.01.006","article-title":"The relationship between total anticholinergic burden (ACB) and early in-patient hospital mortality and length of stay in the oldest old aged 90\u00a0years and over admitted with an acute illness","volume":"59","author":"Kidd","year":"2014","journal-title":"Arch Gerontol Geriatr"},{"issue":"4","key":"10.1016\/j.purol.2018.03.001_bib0350","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ageing\/24.4.287","article-title":"Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial","volume":"24","author":"Szonyi","year":"1995","journal-title":"Age Ageing"},{"issue":"6","key":"10.1016\/j.purol.2018.03.001_bib0355","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1046\/j.1532-5415.2001.49144.x","article-title":"Tolterodine: a safe and effective treatment for older patients with overactive bladder","volume":"49","author":"Malone-Lee","year":"2001","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"10.1016\/j.purol.2018.03.001_bib0360","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/nau.22252","article-title":"Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials","volume":"31","author":"DuBeau","year":"2012","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"10.1016\/j.purol.2018.03.001_bib0365","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1046\/j.1532-5415.2002.50203.x","article-title":"Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients","volume":"50","author":"Zinner","year":"2002","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.purol.2018.03.001_bib0370","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1464-410X.2010.09519.x","article-title":"Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged\u226575years) with overactive bladder syndrome","volume":"107","author":"Sand","year":"2011","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.purol.2018.03.001_bib0375","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjopharm.2006.03.004","article-title":"Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis","volume":"4","author":"Wagg","year":"2006","journal-title":"Am J Geriatr Pharmacother"},{"issue":"5","key":"10.1016\/j.purol.2018.03.001_bib0380","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1532-5415.2008.01680.x","article-title":"Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence","volume":"56","author":"Lackner","year":"2008","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"10.1016\/j.purol.2018.03.001_bib0385","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.juro.2013.08.027","article-title":"Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial","volume":"191","author":"Dubeau","year":"2014","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.purol.2018.03.001_bib0390","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.urology.2010.03.097","article-title":"Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder","volume":"76","author":"Kraus","year":"2010","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.purol.2018.03.001_bib0395","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2013.01.002","article-title":"Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study","volume":"64","author":"Wagg","year":"2013","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.purol.2018.03.001_bib0400","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/ageing\/afu017","article-title":"The efficacy and tolerability of the \u03b23-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients","volume":"43","author":"Wagg","year":"2014","journal-title":"Age Ageing"},{"issue":"10","key":"10.1016\/j.purol.2018.03.001_bib0405","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1185\/03007X226294","article-title":"Darifenacin treatment of patients > or = 65\u00a0years with overactive bladder: results of a randomized, controlled, 12-week trial","volume":"23","author":"Chapple","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.purol.2018.03.001_bib0410","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.eururo.2005.05.009","article-title":"Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3\u00a0selective receptor antagonist","volume":"48","author":"Foote","year":"2005","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2018.03.001_bib0415","first-page":"243","article-title":"A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women","volume":"15","author":"Sand","year":"2004","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"issue":"9","key":"10.1016\/j.purol.2018.03.001_bib0420","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1701-2163(16)32604-4","article-title":"Randomized trial of oxybutynin extended versus immediate release for women aged 65\u00a0older with overactive bladder: lessons learned from conducting a trial","volume":"29","author":"Minassian","year":"2007","journal-title":"J Obstet Gynaecol Can"},{"issue":"2","key":"10.1016\/j.purol.2018.03.001_bib0425","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1185\/03007995.2010.541433","article-title":"Tolerability of solifenacin and oxybutynin immediate release in older (>65years) and younger (\u226465years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study","volume":"27","author":"Herschorn","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.purol.2018.03.001_bib0430","first-page":"739","article-title":"Re: solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial","volume":"191","author":"Wein","year":"2014","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.purol.2018.03.001_bib0435","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2013.01.032","article-title":"Overactive bladder medical management in the elderly: it is time to go beyond the tip of the iceberg","volume":"64","author":"Cornu","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2018.03.001_bib0440","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2013.02.029","article-title":"Reply from authors re: Jean-Nicolas Cornu. Overactive bladder medical management in the elderly: it is time to go beyond the tip of the iceberg","volume":"64","author":"Wagg","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2018.03.001_bib0445","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2165\/00002018-200831060-00005","article-title":"Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study","volume":"31","author":"Michel","year":"2008","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.purol.2018.03.001_bib0450","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1365-2125.2008.03298.x","article-title":"QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman","volume":"66","author":"Asajima","year":"2008","journal-title":"Br J Clin Pharmacol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708718300605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708718300605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:30:19Z","timestamp":1761114619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708718300605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1166708718300605"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2018.03.001","relation":{},"ISSN":["1166-7087"],"issn-type":[{"type":"print","value":"1166-7087"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effets cardio-vasculaires des traitements anticholinergiques \u00e0 vis\u00e9e v\u00e9sicale chez la personne \u00e2g\u00e9e\u00a0: une revue","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2018.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}